A Phase III, open-label, randomized study comparing local radiation therapy alone or in combination with obinutuzumab in patients with early-stage follicular lymphoma (the GAZEBO study by the Italian Lymphoma Foundation).
Contact Information for Access
Status
ATTIVO
Objective of the study
The purpose of the study is to evaluate the superiority of treatment with obinutuzumab compared to radiation therapy alone.
Follicular lymphoma.
ClinicalTrials.gov ID NCT05929222
Sponsor: Italian Lymphoma Foundation - ETS
Medication
Obinutuzumab + radiation therapy vs. radiation therapy
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients diagnosed with follicular lymphoma.
View the full study Back to search page